BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Interim Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 12:00 p.m. Eastern Time at the New York Hilton Midtown.
The fireside chat will be broadcast live and archived on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.
About iBio, Inc.
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
Contact:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.84 |
| Daily Change: | 0.05 6.55 |
| Daily Volume: | 2,311,845 |
| Market Cap: | US$13.560M |
June 24, 2025 June 23, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
